Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of false and misleading statements regarding the company's financial health and operational challenges, particularly related to its High-Value Products portfolio and SmartDose device [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false statements and failing to disclose significant destocking issues in their High-Value Products portfolio [4]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [4]. - The allegations also include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through a series of disclosures, culminating on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025 [5]. - West attributed the disappointing guidance to contract manufacturing challenges, including the loss of two major customers transitioning to in-house manufacturing [5]. - Following this news, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [5]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6].

Core Viewpoint - Freshworks Inc. (NASDAQ: FRSH) has experienced a significant decline of 72% from its all-time high (ATH) in 2021, with a year-to-date return of negative 7.6% [1] Company Performance - The stock's poor performance may lead many investors to dismiss it, but a focus on fundamentals is essential for a comprehensive analysis [1] Investment Strategy - The analysis emphasizes the importance of identifying strong businesses at reasonable prices for long-term investment, with a particular interest in technology companies and a global investment perspective [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Krispy Kreme, Inc. due to allegations of misleading statements and a significant decline in financial performance, particularly related to its partnership with McDonald's [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Krispy Kreme between February 25, 2025, and May 7, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Krispy Kreme, with a deadline of July 15, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Financial Performance - Krispy Kreme reported net revenue of $375.2 million for Q1 2025, reflecting a decline of 15.3% compared to the previous year [5]. - The company also reported a net loss of $33.4 million for Q1 2025, compared to a net loss of $6.7 million in the prior year [5]. - Following the release of these financial results, Krispy Kreme's share price fell by 24.71%, or $1.07 per share, closing at $3.26 on May 8, 2025 [5]. Group 3: Allegations Against Krispy Kreme - The complaint alleges that Krispy Kreme and its executives made false or misleading statements regarding the demand for its products at McDonald's locations, which significantly declined after the initial marketing launch [4]. - It is claimed that the partnership with McDonald's was not profitable and posed substantial risks to maintaining the partnership, leading to a pause in expansion plans [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of false and misleading statements regarding the company's financial health and Medicaid cost management [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elevance between April 18, 2024, and October 16, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance and its executives violated federal securities laws by making false statements and failing to disclose the true nature of rising Medicaid costs [4]. - On July 17, 2024, Elevance disclosed an expectation of increased second-half utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - Further revelations on October 17, 2024, indicated that Elevance missed consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price drop of $52.61 per share, or 10.6% [6]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [7]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi encourages individuals with information regarding Elevance's conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm for legal options [1]. - The court-appointed lead plaintiff will represent the interests of the class and any member can move to serve as lead plaintiff [7]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false statements and failing to disclose critical information about the ENVISION clinical study [4]. - Specific allegations include the study's lack of a concurrent control arm, which undermined the ability to demonstrate the drug's effectiveness, and the company's disregard for FDA warnings regarding study design [4]. - As a result of these issues, there was a substantial risk that the new drug application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's prospects [4]. Group 3: Stock Price Impact - Following the FDA's briefing document questioning the effectiveness of UGN-102, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [5]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, the stock price dropped by $3.37, or 44.7%, closing at $4.17 per share on May 21, 2025 [6].

Save yourself thousands of dollars by creating a portfolio that pays you to hold it. No selling required to fund your retirement dreams. Tired of going it alone or visiting a financial advisor who just doesn't seem to care? Join our lively group! Our Income Method generates strong returns, making retirement investing less stressful and straightforward .Features include: model portfolio with buy/sell alerts, preferred and baby bond portfolios for more conservative investors, vibrant and active chat with acce ...

We all want to find that one investment that can make us huge returns. In the past, Visa (V -5.01%) has done just that.The world's dominant payments processing entity has produced a total return of 2,880% since its initial public offering (IPO) in 2008. This means that had you been able to make a $10,000 investment in this top financial stock back then, you'd be staring at $298,000 in your portfolio today. Shares now trade in record territory. And the company's market cap is at $721 billion. But if you buy ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Civitas To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Civitas between February 27, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNew ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, bot ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...